Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
BACKGROUND: B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the expansion of CD5+ malignant B lymphocytes. Recent discoveries have shown that double-negative T (DNT) cells, double-positive T (DPT) cells, and natural killer T (NKT)-cells may be involved in tumor surveillance.
METHODS: A detailed immunophenotypic analysis of the peripheral blood T-cell compartment of 50 patients with B-CLL (classified in three prognostic groups) and 38 healthy donors (as controls) matched for age was performed. The samples were analyzed by flow cytometry using a stain-lyse-no wash technique and a comprehensive six-color antibody panels.
RESULTS: Our data confirmed a reduction in percentage values and an increase in absolute values of T lymphocytes in patients with B-CLL, as already reported. In particular, DNT, DPT, and NKT-like percentages were significantly lower than in the controls, except for NKT-like in the low-risk prognostic group. Moreover, a significant rise in the absolute counts of DNT cells in each prognostic group and in the low-risk prognostic group of NKT-like cells was found. A significant correlation of the absolute values of NKT-like cells in the intermediate-risk prognostic group versus B cells was observed. Furthermore, we analyzed whether the increase in T cells was related to the subpopulations of interest. Only DNT cells were positively correlated with the increase in CD3+ T lymphocytes, regardless of the stage of the disease, supporting the hypothesis that this T-cell subset plays a key role in the immune T response in B-CLL.
CONCLUSION: These early results supported that DNT, DPT, and NKT-like subsets may be related to disease progression and should encourage further studies aimed at identifying the potential immune surveillance role of these minority T subpopulations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancer medicine - 12(2023), 12 vom: 18. Juni, Seite 13241-13255 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Valvano, Luciana [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.07.2023 Date Revised 05.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cam4.6015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356436403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356436403 | ||
| 003 | DE-627 | ||
| 005 | 20231226070446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.6015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356436403 | ||
| 035 | |a (NLM)37140360 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Valvano, Luciana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.07.2023 | ||
| 500 | |a Date Revised 05.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the expansion of CD5+ malignant B lymphocytes. Recent discoveries have shown that double-negative T (DNT) cells, double-positive T (DPT) cells, and natural killer T (NKT)-cells may be involved in tumor surveillance | ||
| 520 | |a METHODS: A detailed immunophenotypic analysis of the peripheral blood T-cell compartment of 50 patients with B-CLL (classified in three prognostic groups) and 38 healthy donors (as controls) matched for age was performed. The samples were analyzed by flow cytometry using a stain-lyse-no wash technique and a comprehensive six-color antibody panels | ||
| 520 | |a RESULTS: Our data confirmed a reduction in percentage values and an increase in absolute values of T lymphocytes in patients with B-CLL, as already reported. In particular, DNT, DPT, and NKT-like percentages were significantly lower than in the controls, except for NKT-like in the low-risk prognostic group. Moreover, a significant rise in the absolute counts of DNT cells in each prognostic group and in the low-risk prognostic group of NKT-like cells was found. A significant correlation of the absolute values of NKT-like cells in the intermediate-risk prognostic group versus B cells was observed. Furthermore, we analyzed whether the increase in T cells was related to the subpopulations of interest. Only DNT cells were positively correlated with the increase in CD3+ T lymphocytes, regardless of the stage of the disease, supporting the hypothesis that this T-cell subset plays a key role in the immune T response in B-CLL | ||
| 520 | |a CONCLUSION: These early results supported that DNT, DPT, and NKT-like subsets may be related to disease progression and should encourage further studies aimed at identifying the potential immune surveillance role of these minority T subpopulations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a chronic lymphocytic leukemia | |
| 650 | 4 | |a double-negative T cells | |
| 650 | 4 | |a double-positive T cells | |
| 650 | 4 | |a flow cytometry | |
| 650 | 4 | |a immune surveillance | |
| 650 | 4 | |a lymphocytes | |
| 650 | 4 | |a natural killer T-like cells | |
| 700 | 1 | |a Nozza, Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a D'Arena, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a D'Auria, Fiorella |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Luciana |e verfasserin |4 aut | |
| 700 | 1 | |a Pietrantuono, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Mansueto, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Villani, Oreste |e verfasserin |4 aut | |
| 700 | 1 | |a D'Agostino, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Lamorte, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Calice, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Statuto, Teodora |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g 12(2023), 12 vom: 18. Juni, Seite 13241-13255 |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:12 |g day:18 |g month:06 |g pages:13241-13255 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.6015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 12 |b 18 |c 06 |h 13241-13255 | ||